Healthcare
•3759 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3759)
| Company | Market Cap | Price |
|---|---|---|
|
QGEN
Qiagen N.V.
QIAGEN directly manufactures diagnostic instruments (e.g., QIAstat-Dx, QIAcuity, QIAsymphony Connect) and automated platforms.
|
$10.17B |
$45.42
+0.45%
|
|
BAX
Baxter International Inc.
Novum IQ infusion platform is a medical device platform core to Baxter's Medical Devices & Equipment offerings.
|
$10.03B |
$19.52
+1.93%
|
|
BMRN
BioMarin Pharmaceutical Inc.
BioMarin's core commercial therapies (VOXZOGO for skeletal disorders and enzyme replacement therapies like PALYNZIQ, VIMIZIM, NAGLAZYME) are all in the rare diseases space, fitting the Biotech - Rare Diseases investable theme.
|
$10.01B |
$52.12
-2.24%
|
|
CRL
Charles River Laboratories International, Inc.
CRL operates as a contract research organization, outsourcing preclinical drug development services.
|
$9.75B |
$198.12
+2.64%
|
|
ARWR
Arrowhead Pharmaceuticals, Inc.
Arrowhead's core platform and lead programs are based on RNA interference (siRNA) therapeutics, i.e., RNAi Therapeutics.
|
$9.46B |
$68.33
-2.51%
|
|
HSIC
Henry Schein, Inc.
Henry Schein directly distributes dental equipment to dental practices, aligning with its core product offerings.
|
$9.38B |
$77.41
+1.12%
|
|
RNA
Avidity Biosciences, Inc.
Direct product modality: oligonucleotide therapeutics (AOC platform) delivering RNA payloads.
|
$9.25B |
$71.86
+0.03%
|
|
CORT
Corcept Therapeutics Incorporated
Corcept develops and commercializes oral small-molecule cortisol modulators (Korlym, relacorilant) for hypercortisolism and oncology, fitting 'Oral Small Molecule Therapeutics'.
|
$9.20B |
$87.32
-0.76%
|
|
TECH
Bio-Techne Corporation
Bio-Techne's core business includes recombinant proteins and enzymes used as highly characterized reagents across life-science workflows.
|
$9.13B |
$58.72
+0.35%
|
|
VRNA
Verona Pharma plc
Verona's Ohtuvayre (ensifentrine) is a small-molecule therapeutic used for COPD management.
|
$9.10B |
$106.91
|
|
MOH
Molina Healthcare, Inc.
MOH primarily provides health insurance products (Medicaid, Medicare, Marketplace) including integrated dual-eligible plans.
|
$9.02B |
$166.60
-1.13%
|
|
DVA
DaVita Inc.
DaVita operates clinical laboratory testing facilities and diagnostic services as part of its dialysis and kidney care offerings.
|
$8.58B |
$120.11
-1.02%
|
|
LNC
Lincoln National Corporation
LNC provides disability insurance as part of its group protection/employee benefits offerings.
|
$8.57B |
$45.22
+0.36%
|
|
RGC
Regencell Bioscience Holdings Limited
Regencell Bioscience focuses on neuropsychiatric drug development for ADHD/ASD, aligning with Neuropsychiatric Drug Development.
|
$8.53B |
$16.94
+2.05%
|
|
BIO
Bio-Rad Laboratories, Inc.
Bio-Rad directly manufactures and sells diagnostic instruments and related equipment used in clinical laboratories.
|
$8.33B |
$307.51
-0.20%
|
|
BPMC
Blueprint Medicines Corporation
AYVAKIT is Blueprint Medicines' flagship oncology/hematology drug; directly produced and marketed, fitting Biotech - Oncology.
|
$8.27B |
$129.46
|
|
HIMS
Hims & Hers Health, Inc.
Laboratory testing & advisory services core to in-house lab capabilities.
|
$8.19B |
$36.24
-2.61%
|
|
ATR
AptarGroup, Inc.
Aptar markets proprietary drug-delivery platforms (e.g., nasal/inhalation delivery) which are core to its pharma offering.
|
$8.06B |
$122.20
+0.61%
|
|
AHR
American Healthcare REIT, Inc.
Healthcare Services & Facilities: reflects management and operation of healthcare facilities within the portfolio.
|
$7.96B |
$47.20
-0.12%
|
|
AVTR
Avantor, Inc.
Avantor provides Laboratory Testing & Advisory Services, aligning with outsourced testing and regulatory support offerings.
|
$7.69B |
$11.27
+0.90%
|
|
NUVL
Nuvalent, Inc.
Nuvalent is a oncology-focused biotechnology company developing targeted cancer therapies (ROS1/ALK inhibitors), fitting Biotech - Oncology.
|
$7.57B |
$104.80
|
|
RYTM
Rhythm Pharmaceuticals, Inc.
Rhythm's core business is developing and commercializing therapies for ultra-rare diseases (e.g., setmelanotide for MC4R pathway deficiencies, BBS), a hallmark of rare-disease biotech.
|
$7.47B |
$112.53
-0.91%
|
|
MASI
Masimo Corporation
Primary revenue comes from patient monitoring devices and systems sold to healthcare providers.
|
$7.46B |
$137.31
-0.74%
|
|
CYTK
Cytokinetics, Incorporated
Cytokinetics' core programs target cardiovascular diseases (aficamten for hypertrophic cardiomyopathy, omecamtiv mecarbil and ulacamten), making 'Cardiovascular Drugs' the primary investable theme.
|
$7.44B |
$62.14
-1.91%
|
|
HALO
Halozyme Therapeutics, Inc.
Halozyme's ENHANZE is a proprietary drug-delivery platform enabling rapid, subcutaneous administration of large-volume biologics.
|
$7.42B |
$63.45
+1.99%
|
|
ABVX
Abivax S.A.
Obefazimod is an oral small-molecule therapeutic targeting inflammatory pathways in IBD.
|
$7.42B |
$118.69
-5.46%
|
|
MTSR
Metsera, Inc.
Metsera is a clinical-stage biotech developing peptide-based therapeutics (MET-097i, MET-233i, MET-97o, MET-224o), i.e., Peptide Therapeutics.
|
$7.41B |
$70.53
+0.04%
|
|
MRUS
Merus N.V.
Company develops multispecific antibody therapeutics for oncology, including lead candidates like petosemtamab and BIZENGRI.
|
$7.32B |
$96.84
-0.09%
|
|
AXSM
Axsome Therapeutics, Inc.
Axsome's revenue drivers Auvelity and Sunosi and pipeline products are oral small-molecule therapeutics.
|
$7.30B |
$146.34
-1.23%
|
|
VOYA
Voya Financial, Inc.
VOYA provides health insurance products and related stop‑loss/health solutions to employers, a central part of its Workplace Solutions.
|
$7.23B |
$74.94
+1.65%
|
|
KRYS
Krystal Biotech, Inc.
Krystal Biotech's core HSV-1 gene therapy platform and lead product VYJUVEK directly represent a gene therapy business.
|
$7.03B |
$243.09
-0.64%
|
|
BRKR
Bruker Corporation
Bruker directly manufactures diagnostic instrumentation and analytical equipment such as MALDI Biotyper and other diagnostic/imaging instruments.
|
$6.93B |
$45.67
+1.21%
|
Showing page 6 of 38 (3759 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
